

Alkyl Amines Chemicals Limited



Reg. Office: 401-407, Nirman Vyapar Kendra, Plot No. 10, Sector 17, Vashi, Navi Mumbai - 400 703. INDIA Tel.: 022-6794 6600 • Fax: 022-6794 6666 • E-mail: alkyl@alkylamines.com • Web: www.alkylamines.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30,2020

(Rs.in Lakhs)

| No | | (Except per share | | | | |
|--|------|---|--------------------------|-----------|---------------------|---------------------|
| No Particulars Jun 30, 2020 Mar 31, 2020 Jun 30, 2019 Mar 31, 2020 Mar 31, 2021 | Sr. | | Quarter ended Year ended | | | |
| Revenue from Operations | | Particulars | Jun 30. 2020 | | Jun 30, 2019 | Mar 31, 2020 |
| Other Income | | | | | Unaudited | Audited |
| | | Devenue from Oracelia | 04 545 04 | 22 476 51 | 26 623 05 | 99,287.76 |
| III Total Revenue (I+II) 24,633.27 23,738.44 26,756.31 99,988 IV. Expenses 10,793.45 11,054.36 13,649.71 47,622 Changes in Inventories of Finished Goods 19.81 (264.15) 1,061.30 827 Changes in Inventories of Finished Goods 19.81 (264.15) 1,061.30 827 Changes in Inventories of Finished Goods 19.81 (264.15) 1,061.30 827 Changes in Inventories of Finished Goods 19.81 (264.15) 1,061.30 827 Changes in Inventories of Finished Goods 19.81 (264.15) 1,061.30 827 Changes in Inventories of Finished Goods 19.81 (264.15) 1,061.30 827 Changes in Inventories of Finished Goods 19.81 (264.15) 1,061.30 827 Changes in Inventories of Finished Goods 19.81 (264.15) 1,061.30 827 Changes in Inventories of Finished Goods 19.81 (264.15) 1,061.30 827 Changes in Inventories of Expenses 19.81 (264.15) 1,061.30 827 Changes in Inventories of Expenses 3,921.11 4,232.32 4,327.63 18.172 Changes in Inventories of Expenses 3,972.11 4,232.32 4,327.63 18.172 Changes in Inventories of Expenses 1,661.90 6,110.60 5,045.45 22,686 Changes in Inventories of Expenses 1,661.90 6,110.60 5,045.45 22,686 Changes in Inventories of Expenses 1,545.96 1,453.14 1,499.11 5,403 Changes in Inventories of Expenses 1,545.96 1,453.14 1,499.11 5,403 Changes in Inventories of Expenses 1,683.77 1,189.82 1,536.16 4,442 Inventories of Expenses 1,683.77 1,189.82 1,536.1 | | | 50. | | *0 | 701.16 |
| No. Expenses Cost of Materials Consumed 10,793.45 11,054.36 13,649.71 47,621 Changes in Inventories of Finished Goods 19.81 (264.15) 1,061.30 827 and Work-in-Progress Employee benefit costs 1.991.69 1,695.74 1,668.96 6.964 1,0051.20 | _ | | | | | 99,988.92 |
| Cost of Materials Consumed Changes in Inventories of Finished Goods and Work-in-Progress Employee benefit costs Finance Costs Depreciation and Amortisation Expense Other Expenses Other Expenses Other Expenses Finance Costs Total Expenses (IV) Total Expenses (IV) Total Expenses (IV) Profit before Exceptional Items and Tax (III-IV) Frofit before Exceptional Items Total Expenses Current Tax For Instance (IV) Frofit before tax (V+VI) Frofit befo | | Total Nevellue (I+II) | 24,633.27 | 25,750. | | |
| Changes in Inventories of Finished Goods and Work-in-Progress | IV. | | | // | | 47 004 00 |
| and Work-in-Progress Employee benefit costs Employee benefit costs Finance Costs Depreciation and Amortisation Expense Other Expenses Other Expenses Other Expenses Total Expenses (IV) Total Expenses (IV) Profit before Exceptional Items and Tax (III-IV) Exceptional Items Total Expenses Total Expenses Total Expenses (IV) Profit before Exceptional Items and Tax (III-IV) Expenses Total Tax Expense Total Tax Expenses Total Tax Expenses Total Tax Exp | | N 124 | ' | | VI * VIV **** | 47,621.68 |
| Finance Costs 192.35 189.32 363.32 1,025 1 | | | 19.81 | (264.15) | 1,061.30 | 827.78 |
| Depreciation and Amortisation Expense 701.96 720.25 639.94 2,690 | | Employee benefit costs | 1,991.69 | 1,695.74 | 1,668.96 | 6,964.15 |
| Other Expenses 3,972.11 4,232.32 4,327.63 18,172 | | Finance Costs | 192.35 | 189.32 | 363.32 | 1,025.39 |
| Total Expenses (IV) 17,671.37 17,627.84 21,710.86 77,302 | | Depreciation and Amortisation Expense | 701.96 | 720.25 | | 2,690.98 |
| V. Profit before Exceptional Items and Tax (III-IV) Exceptional Items Foundation Found | | Other Expenses | 3,972.11 | 4,232.32 | | 18,172.17 |
| VI. Exceptional Items - - 3,284 VII. Profit before tax (V+VI) 6,961.90 6,110.60 5,045.45 25,970 VIII Tax Expense : . | | Total Expenses (IV) | 17,671.37 | 17,627.84 | 21,710.86 | 77,302.15 |
| VII. Profit before tax (V+VI) 6,961.90 6,110.60 5,045.45 25,970 | | | 6,961.90 | 6,110.60 | 5,045.45 | 22,686.77 |
| VIII Tax Expense : | | | | - | | |
| Current Tax | | | 6,961.90 | 6,110.60 | 5,045.45 | 25,970.93 |
| Deferred Tax | VIII | • | 4.545.00 | 4 450 44 | 4 400 44 | 5 402 FE |
| Tax adjustments of earlier years (7.53) 3.42 - 69 Total Tax Expenses 1,683.77 1,189.82 1,536.16 4,442 IX. Net Profit for the Period/Year (VII-VIII) 5,278.13 4,920.78 3,509.29 21,528 X. Other Comprehensive Income/ (Expense) a) Items that will not be reclassified to profit or loss - Remeasurement gain/(losses) on defined benefit b) Income tax relating to items that will not be reclassified to profit or loss c) Items that may be reclassified to profit or loss - Deferred gains/(losses) on cash flow hedges reserves d) Income tax relating to items that may be reclassified to profit or loss Other Comprehensive Income / (Expense) for the period/year (Net of Tax) XI. Total Comprehensive Income for the period/year 5,257.91 4,910.14 3,463.52 21,397 XII. Paid up Share Capital 1,019.82 1,019.82 1,019.82 1,019.82 IXIII Face Value of Share (Rs) 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.0 | | | | | | |
| Total Tax Expenses 1,683.77 1,189.82 1,536.16 4,442 IX. Net Profit for the Period/Year (VII-VIII) 5,278.13 4,920.78 3,509.29 21,528 IX. Net Profit for the Period/Year (VII-VIII) 5,278.13 4,920.78 3,509.29 21,528 IX. Other Comprehensive Income/ (Expense) (79.49) (13.13) (65.16) (171 | | | Sec. 27. 1 | ` | 37.05 | (1,030.04) 69.30 |
| IX. Net Profit for the Period/Year (VII-VIII) 5,278.13 4,920.78 3,509.29 21,528 X. Other Comprehensive Income/ (Expense) a) Items that will not be reclassified to profit or loss - Remeasurement gain/(losses) on defined benefit b) Income tax relating to items that will not be reclassified to profit or loss 0.86 - 0.8 | | | | | 1 525 16 | |
| X. Other Comprehensive Income/ (Expense) a) Items that will not be reclassified to profit or loss - Remeasurement gain/(losses) on defined benefit b) Income tax relating to items that will not be reclassified to profit or loss c) Items that may be reclassified to profit or loss - Deferred gains/(losses) on cash flow hedges reserves d) Income tax relating to items that may be reclassified to profit or loss - Deferred gains/(losses) on cash flow hedges reserves d) Income tax relating to items that may be reclassified to profit or loss Other Comprehensive Income / (Expense) for the period/year (Net of Tax) XI. Total Comprehensive Income for the period/year XII. Paid up Share Capital Total Comprehensive Income for the period/year 1,019.82 | | | | | | |
| a) Items that will not be reclassified to profit or loss - Remeasurement gain/(losses) on defined benefit b) Income tax relating to items that will not be reclassified to profit or loss c) Items that may be reclassified to profit or loss - Deferred gains/(losses) on cash flow hedges reserves d) Income tax relating to items that may be reclassified to profit or loss Other Comprehensive Income / (Expense) for the period/year (Net of Tax) XI. Total Comprehensive Income for the period/year XII. Paid up Share Capital Table Capital 1,019.82 | IX. | Net Profit for the Period/Year (VII=VIII) | 5,276.13 | 4,920.76 | 3,303.23 | 21,020.12 |
| b) Income tax relating to items that will not be reclassified to profit or loss c) Items that may be reclassified to profit or loss - Deferred gains/(losses) on cash flow hedges reserves d) Income tax relating to items that may be reclassified to profit or loss Other Comprehensive Income / (Expense) for the period/year (Net of Tax) XI. Total Comprehensive Income for the period/year XII. Paid up Share Capital Total Comprehensive Income for the period/year XII. Face Value of Share (Rs) XIV Earnings Per Equity Share Basic (Rs) 17.59 1.82 19.39 4.0 (0.19) - (0 (11.84) (0.19) - (10.64) (45.77) (130 (130 1,019.82 1,019 | Χ. | a) Items that will not be reclassified to profit or loss | (79.49) | (13.13) | (65.16) | (171.17) |
| c) Items that may be reclassified to profit or loss - Deferred gains/(losses) on cash flow hedges reserves d) Income tax relating to items that may be reclassified to profit or loss Other Comprehensive Income / (Expense) for the period/year (Net of Tax) XI. Total Comprehensive Income for the period/year XII. Paid up Share Capital XIII. Face Value of Share (Rs) XIV Earnings Per Equity Share Basic (Rs) 53.52 0.86 - 0 (0.19) - (0 (10.64) (45.77) (130 (45.77) (130 | | | 17.59 | 1.82 | 19.39 | 40.38 |
| d) Income tax relating to items that may be reclassified to profit or loss (11.84) (0.19) - | | c) Items that may be reclassified to profit or loss | 53.52 | 0.86 | | 0.80 |
| Other Comprehensive Income / (Expense) for the period/year (Net of Tax) (20.22) (10.64) (45.77) (130 period/year (Net of Tax) XI. Total Comprehensive Income for the period/year 5,257.91 4,910.14 3,463.52 21,397 XII. Paid up Share Capital 1,019.82 1,019.82 1,019.82 1,019.82 XIII Face Value of Share (Rs) 5.00 5.00 5.00 5 XIV Earnings Per Equity Share Basic (Rs) 25.88 24.13 17.21 105 | | d) Income tax relating to items that may be reclassified to | (11.84) | (0.19) | | (0.18) |
| No. Total Comprehensive Income for the period/year | | | (20.22) | (10.64) | (45.77) | (130.17) |
| XII. Paid up Share Capital XIII. Face Value of Share (Rs) XIV Earnings Per Equity Share Basic (Rs) 1,019.82 | | | (20.22) | (10.04) | (45.77) | (100.17) |
| XIII Face Value of Share (Rs) XIV Earnings Per Equity Share Basic (Rs) 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 | χı. | Total Comprehensive Income for the period/year | 5,257.91 | 4,910.14 | 3,463.52 | 21,397.95 |
| XIIV Earnings Per Equity Share Basic (Rs) 25.88 24.13 17.21 105 | XII. | Paid up Share Capital | 1,019.82 | 1,019.82 | | 1,019.82 |
| Basic (Rs) 25.88 24.13 17.21 105 | XIII | Face Value of Share (Rs) | 5.00 | 5.00 | 5.00 | 5.00 |
| Busio (ito) | ΧIV | Earnings Per Equity Share | | | ه دروالي الأوادي ال | i.s. |
| Diluted (Rs) 25.81 24.06 17.16 105 | | • • • | | 12 120 | 1 2 | 105.55 |
| | | Diluted (Rs) | 25.81 | 24.06 | 17.16 | 105.27 |

Corporate Office: 207 A, Kakad Chambers, 132, Dr. Annie Besant Road Worli, Mumbai - 400 018. INDIA Tel.: 91-22-2493 1385, 6748 8200 • Fax: 91-22-2493 0710 • CIN No : L99999MH1979PLC021796.

ALKYL

Notes

- The above unaudited financial results have been reviewed and recommended by the Audit Committee at their meeting held on August 14, 2020, and approved by the Board of Directors at their meeting on the same date. The Limited Review, as required under Regulation of the SEBI (Listing Obligations and Disclousre Requiremnts) Regulations, 2015, has been completed by the Statutory Auditors for the Quarter ended June 30,2020 and they have expressed an unmodified opinion on the same.
- The Company is primarily engaged in the business of "Specialty Chemicals". Accordingly, there are no reportable Segments.
- The Company is continuously monitoring the lockdown situation due to spread of Covid-19 pandemic from mid-March and regularly assesses the impact of pandemic on its business operations and performance. The Company is in the business of manufacture and sale of essential products, being mainly pharmaceutical intermediates and is well positioned to fulfil its existing orders and contracts. The Company has been able to meet all its operational needs and is in a comfortable liquidity position to meet its financial commitments. There is no impact on capital and financial resources of the Company. The assets have not been impacted as a result of the pandemic. The Company continues to abide by the directives and advisories issued by various Government authorities and evaluate the impact of COVID-19 as the situation evolves. While there has not been materially adverse impact of COVID-19 on the Company's business operations so far, it is extremely difficult to assess future impact. The Company expects that the demand for its products from pharmaceuticals sector will continue and, as such, barring unforeseen circumstances there will not be a significant impact of COVID-19 on the operations of the Company.

Figures for the previous periods have been regrouped and reclassified, wherever necessary.

FOR ALKYL AMINES CHEMICALS LTD.

501-

YOGESH M.KOTHARI
CHAIRMAN & MANAGING DIRECTOR

Place : Mumbai

Date: August 14,2020